Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)Product type:GuidanceProgramme:Diagnostics guidancePublished: 24 August 2023
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer (IPG763)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 6 June 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Endo-SPONGE for treating low rectal anastomotic leak (MTG63)Product type:GuidanceProgramme:Medical technologies guidancePublished: 16 December 2021
Transanal total mesorectal excision for rectal cancer (IPG713)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 15 December 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 January 2021
Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 4 March 2020
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer (IPG659)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 August 2019
Endocuff Vision for assisting visualisation during colonoscopy (MTG45)Product type:GuidanceProgramme:Medical technologies guidancePublished: 7 June 2019
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 25 September 2017Published: 29 March 2017
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 May 2017
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)Product type:GuidanceProgramme:Diagnostics guidancePublished: 10 May 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 March 2017Published: 14 December 2011
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)Product type:GuidanceProgramme:Diagnostics guidancePublished: 22 February 2017
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Microwave ablation for treating liver metastases (IPG553)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 April 2016
Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer (IPG532)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 September 2015
Preoperative high dose rate brachytherapy for rectal cancer (IPG531)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 August 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)Product type:GuidanceProgramme:Diagnostics guidancePublished: 10 December 2014
Combined endoscopic and laparoscopic removal of colonic polyps (IPG503)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 September 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2014
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2012Published: 24 January 2007
Endoscopic radical inguinal lymphadenectomy (IPG398)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 June 2011
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Radiofrequency ablation for colorectal liver metastases (IPG327)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 December 2009
Laparoscopic surgery for colorectal cancer (TA105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2006
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2006
Computed tomographic colonography (virtual colonoscopy) (IPG129)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 June 2005
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (IPG56)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 April 2004
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2003
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 July 2024
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Colon cancer (adjuvant) - irinotecan [ID379]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selective internal radiation therapy for unresectable colorectal metastases in the liverStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
The Extraperitoneal approach to left sided colorectal resections ( EXPERTS) ProcedureStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC